Sai Parenterals Limited
All news and filings related to Sai Parenterals Limited.
View all news & filings- Medium impact
Sai Parenterals Limited Concludes 25th AGM; All Resolutions Passed
Sai Parenterals Limited held its 25th AGM on September 10, 2026. The meeting approved the financial statements for FY26, re-appointed key directors including MD Anil Kumar Karusala, and ratified several corporate actions. All 12 resolutions presented were passed.
Read the summary - Medium impact
Sai Parenterals' Australian arm renews 3-year OTC deal worth AUD 30M (₹204 Cr)
Sai Parenterals' Australian subsidiary, Noumed Pharmaceuticals, renewed a 3-year OTC Medicines Supply Agreement valued at AUD 30 million (₹204 crore). This extends the total contracted Australian OTC book to AUD 232 million (₹1,506 crore). The deal involves expanded product portfolio and management of the full value chain.
Read the summary - Medium impact
Sai Parenterals Subsidiary Renews AUD 30M OTC Supply Pact with Australian Pharmacy Chain
Sai Parenterals' subsidiary, Noumed Pharmaceuticals, renewed an OTC Medicines Supply Agreement with an Australian pharmacy chain. The 3-year contract is valued at AUD 30 million (approx. ₹204 Crores). The agreement starts from August 24th, 2026.
Read the summary - Low impact
Sai Parenterals to Participate in Analyst/Institutional Investor Meeting on Aug 31, 2026
Sai Parenterals Limited will participate in an Analyst/Institutional Investor Meeting on Monday, 31st August, 2026. The physical group meeting in Mumbai will commence at 10:00 AM onwards and is hosted by Strategic Growth Advisors Pvt. Ltd. Discussions will be limited to publicly available information.
Read the summary - Medium impact
Sai Parenterals to seek shareholders' nod for IPO fund utilization variation
Sai Parenterals Limited will seek shareholder approval to reallocate IPO funds. Rs. 838.34 million will be used to acquire a 60% stake in Saicriti Pharma, and Rs. 180.23 million for a stake in Prathyak Laboratories. The 25th AGM is on September 10, 2026.
Read the summary - Medium impact
Sai Parenterals to change IPO fund utilization for acquisitions
Sai Parenterals Limited proposes to change IPO fund utilization by acquiring stakes in Saicriti Pharma (₹83.83 crore) and Prathyak Laboratories (₹18.02 crore). The 25th AGM is on September 10, 2026, to approve this variation.
Read the summary - Low impact
Sai Parenterals Limited Announces Book Closure for 25th AGM on Sep 10, 2026
Sai Parenterals Limited will hold its 25th AGM on September 10, 2026. The book closure is from September 4 to September 10, 2026. September 3, 2026, is the record date for determining voting rights.
Read the summary - Low impact
Sai Parenterals Announces 25th AGM on Sep 10, 2026
Sai Parenterals Limited will hold its 25th Annual General Meeting on September 10, 2026, at 11:00 AM via Video Conference. The annual report and AGM notice were dispatched on August 19, 2026.
Read the summary - High impact
Sai Parenterals Limited: Transcript of Q1 FY'27 Earnings Call Released
Sai Parenterals Limited released its Q1 FY'27 earnings call transcript. Consolidated revenue was ₹182 crore, with PAT at ₹8 crore. The company plans to redeploy ₹101.85 crore of IPO funds for majority stakes in Saicriti Pharma (₹83.83 crore) and Prathyak Laboratories (₹15 crore). The Australian facility is on track for completion by January 2027.
Read the summary - Low impact
Sai Parenterals: Audio Recording of Q1 FY27 Earnings Call Available
Sai Parenterals Limited has released the audio recording of its Q1 FY27 earnings call held on August 12, 2026. The recording is available on the company's website for investors.
Read the summary - High impact
Sai Parenterals Q1FY27 Revenue at ₹182 Cr, Up 175% YoY; Acquires Stakes in Pharma Assets
Sai Parenterals reported Q1 FY27 consolidated revenue of ₹182.4 crore, up 175% YoY. PAT was ₹7.9 crore. The company will redeploy ₹101.85 crore of IPO proceeds to acquire majority stakes in Saicriti Pharma (60% for ₹83.83 Cr) and Prathyak Laboratories (60% for ₹18.02 Cr). Acquisition of Prathyak to complete by Sep 30, 2026.
Read the summary - Low impact
Sai Parenterals IPO Funds Utilisation: No Deviation Reported for Q1 FY27
Sai Parenterals Limited reported no deviation in IPO fund utilization for the quarter ended June 30, 2026. The company raised ₹285 crore through its IPO. Funds were utilized for capacity expansion, R&D, debt repayment, working capital, and general corporate purposes.
Read the summary - High impact
Sai Parenterals Board Approves Q1 FY27 Results, Key Management Changes, and Strategic Acquisitions
Sai Parenterals reported Q1 FY27 results with standalone profit after tax at ₹88.75 million and consolidated profit after tax at ₹79.23 million. The board approved the re-appointment of Anil Kumar Karusala as MD and Vijitha Gorrepati as Whole-time Director. Mr. Kunal Kakumanu joins as Executive Director. The company will acquire stakes in Saicriti Pharma (₹838.34 million) and Prathyak Laboratories (₹150 million). The AGM is scheduled for September 10, 2026.
Read the summary - High impact
Sai Parenterals Board Approves Q1 FY27 Results, Key Reappointments & IPO Fund Diversion
Sai Parenterals Limited reported Q1 FY27 results with standalone revenue at ₹52.78 crore and consolidated revenue at ₹178.67 crore. The board approved re-appointments of Anil Kumar Karusala as MD and Vijitha Gorrepati as Whole-time Director. IPO proceeds of ₹83.83 crore will be diverted to acquire Saicriti Pharma and ₹18.02 crore to acquire Prathyak Laboratories. The AGM is scheduled for September 10, 2026.
Read the summary - Low impact
Sai Parenterals Limited Schedules Q1 FY27 Earnings Conference Call for Aug 12
Sai Parenterals Limited will hold an Earnings Conference Call on August 12, 2026, at 2:30 p.m. IST. The call will discuss the financial and operational performance for the quarter ended June 30, 2026. Participants include the CMD, CEO of Noumed, and CFO.
Read the summary - Low impact
Sai Parenterals Files SEBI Compliance Certificate for Q1 FY27
Sai Parenterals Limited filed a SEBI compliance certificate for the quarter ended June 30, 2026. The company confirmed details of securities dematerialization to stock exchanges, as per Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. A confirmation letter from RTA Bigshare Services Private Limited was enclosed.
Read the summary - Low impact
Sai Parenterals Appoints Secretarial, Internal, and Cost Auditors; Explores Growth
Sai Parenterals Limited appointed M/s. Aakanksha Dubey & Co. as Secretarial Auditors for five years (2026-27 to 2030-31). M/s. NSVR & Associates LLP and M/s. Sai Krishna & Associates were appointed as Internal and Cost Auditors, respectively, for FY 2026-27. The MD is authorized to explore growth opportunities.
Read the summary - Low impact
Sai Parenterals to Participate in Analyst/Institutional Investor Meeting on July 2, 2026
Sai Parenterals Limited will participate in a virtual Analyst/Institutional Investor Meeting on July 2, 2026, hosted by Axis Capital. Discussions will be limited to publicly available information.
Read the summary - Low impact
Sai Parenterals: Trading Window Closed July 1 to Post Q1 FY27 Results Declaration
Sai Parenterals Limited will close its trading window from July 1, 2026. The window will reopen 48 hours after the declaration of un-audited financial results for the quarter ending June 30, 2026. The board meeting date for results declaration will be intimated later.
Read the summary - High impact
Sai Parenterals Releases Q4 & FY26 Earnings Call Transcript
Sai Parenterals released its Q4 & FY26 earnings call transcript. FY26 consolidated revenue grew 133% to ₹381 crore. The company targets ₹750 crore revenue for FY27 with a 17% EBITDA margin. A ₹440 crore capex program is underway, including an Australian facility expansion and Indian upgrades, expected to contribute from FY28.
Read the summary - Medium impact
Sai Parenterals Secures ₹104.5 Crore Order from Philippines' PILL CORP
Sai Parenterals Limited received a purchase order worth USD 11 million (₹104.50 Crores) from PILL CORP, Philippines. The contract is for supplying anti-TB products for 10 years, starting June 1, 2026.
Read the summary - Low impact
Sai Parenterals Q4 FY26 Earnings Call Recording Available
Sai Parenterals Limited has released the audio recording of its Q4 and full year FY26 earnings call held on May 27, 2026. The recording is available on the company's website.
Read the summary - Medium impact
Sai Parenterals Q4FY26 & FY26 Results: Revenue at ₹198 Cr & ₹381 Cr
Sai Parenterals reported Q4 FY26 consolidated revenue of ₹198 crore and FY26 consolidated revenue of ₹381 crore. Standalone FY26 revenue grew 31% to ₹162 crore, with EBITDA up 23% to ₹33 crore and PAT up 64% to ₹17 crore. CDMO revenue surged over 250% YoY. The company aims to expand its global injectable formulations market and capitalize on CDMO opportunities.
Read the summary - High impact
Sai Parenterals Q4 FY26 Revenue Surges 166% to ₹197.93 Cr; PAT Jumps 736%
Sai Parenterals Limited reported Q4 FY26 consolidated revenue of ₹197.93 crore, up 166.65% YoY, with PAT rising 736.04% to ₹13.25 crore. FY26 revenue reached ₹380.99 crore, up 140.37% YoY, with PAT at ₹14.37 crore. The company completed a ₹285 crore IPO in March 2026 and targets ₹750 crore revenue in FY27.
Read the summary - Medium impact
Sai Parenterals Schedules Q4 & FY26 Earnings Conference Call for May 27
Sai Parenterals Limited announced its Q4 and FY26 results on May 23, 2026. The company will host an earnings conference call on May 27, 2026, at 4:00 PM IST to discuss its financial performance. Management, including the MD and CFO, will be present.
Read the summary - Low impact
Sai Parenterals Limited Reports No Deviation in IPO Fund Utilization for Q4 FY26
Sai Parenterals Limited confirmed no deviation in IPO fund utilization for the quarter and year ended March 31, 2026. The company raised ₹285 crore via IPO. Funds were utilized across expansion, R&D, debt repayment, working capital, and general corporate purposes without variation.
Read the summary - Medium impact
Sai Parenterals Board Approves Q4 FY26 & 9MFY26 Results, Auditors Issue Unmodified Opinion
Sai Parenterals Limited's Board approved Q4 FY26 and 9MFY26 results on May 23, 2026. Standalone 9MFY26 revenue was ₹105.46 crore, with PAT ₹8.28 crore. Consolidated 9MFY26 revenue was ₹153.07 crore, with PAT ₹1.10 crore. Audited FY26 standalone revenue ₹124.27 crore, PAT ₹99.49 crore. Consolidated FY26 revenue ₹350.99 crore, PAT ₹131.57 crore. Auditors issued an unmodified opinion.
Read the summary - High impact
Sai Parenterals Board Approves Q4 FY26 & Q3 FY26 Results, Auditors Report
Sai Parenterals Limited's Board approved unaudited financial results for Q3 FY26 and audited results for Q4 FY26. The company also received an unmodified audit opinion for the year ended March 31, 2026. The company is proceeding with its IPO process and has completed a significant acquisition in Noumed Life Sciences.
Read the summary - Low impact
Sai Parenterals IPO Proceeds Utilization Report: No Deviation Noted
Sai Parenterals Limited's Monitoring Agency Report for Q4FY26 confirms no deviation in IPO proceeds utilization. The IPO raised ₹285 crore via fresh issue, with ₹285 crore currently in escrow. All project objectives are on track for completion by Fiscal 2027.
Read the summary - Low impact
Sai Parenterals Limited Issues Compliance Certificate for Q4FY26
Sai Parenterals Limited submitted a compliance certificate for the quarter and year ended March 31, 2026. The company confirmed it has a functional Structured Digital Database (SDD) in place, with proper controls and an 8-year record retention capability. Nine events were captured between January 1, 2026, and March 31, 2026.
Read the summary - Low impact
Sai Parenterals to Lend ₹11.91 Crore to Subsidiary for Downstream Investment
Sai Parenterals Limited approved an unsecured loan of up to AUD 1.75 million (₹11.91 crore) to its wholly-owned subsidiary, Sai Singapore Pte. Ltd. This funding is for downstream investment in its step-down subsidiary, Noumed Pharmaceuticals Pty Limited, Australia. The board meeting concluded on April 20, 2026.
Read the summary - Low impact
Sai Parenterals Authorizes Key Personnel for Material Event Disclosures
Sai Parenterals Limited has authorized Anil Kumar Karusala (CMD), Anil Kumar (CFO), and Shivali Aggarwal (Company Secretary) to determine materiality of events and make disclosures to stock exchanges, as per SEBI regulations.
Read the summary - Low impact
Sai Parenterals Limited: Trading Window Closed for Financial Results Announcement
Sai Parenterals Limited has closed its trading window from April 02, 2026. This is in compliance with SEBI regulations regarding insider trading. The window will reopen 48 hours after the Board Meeting to approve financial results for the quarter ended December 31, 2025, and the year ended March 31, 2026.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio